Patents by Inventor Wen E.

Wen E. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160369341
    Abstract: The present invention relates to a rs6311 test kit, which includes a probe, a primer, and a polymerase chain reaction solution, wherein said probe sequence is as follows: rs6311T-fam: CTGTGAGTGTCTGGC (SEQ. ID. NO. 1) and rs6311C-vic: CTGTGAGTGTCCGGC (SEQ. ID. NO. 2); and said primer sequence is as follows: rs6311-F: AGAGAGAACATAAATAAGGCTAGAAAACAGTA (SEQ. ID. NO. 3) and rs6311-R: CACTGTTGGCTTTGGATGGA (SEQ. ID. NO. 4). The test kit is used to determine genotype of a depression patient, in order to treat the depression patient with a combination of serotonin reuptake inhibitors (SSRI) and low dose risperidone. The actual dose of risperidone and the ratio between SSRIs and risperidone is determined by the genotype of the depression patient. The present invention determines human drug metabolism rate through a single nucleotide polymorphism and provides a platform to adjust the patient's treatment.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 22, 2016
    Inventors: Wen E, Qingmei Kong, Xiaojing Zhang, Hong Shao, Zhenguo Zhao, Shuping Liu, Maomao Li, Xinxia Tian
  • Publication number: 20140162261
    Abstract: The present invention relates to a rs6311 test kit, which includes a probe, a primer, and a polymerase chain reaction solution, wherein said probe sequence is as follows: rs6311T-fam: CTGTGAGTGTCTGGC (SEQ. ID. NO. 1) and rs6311C-vic: CTGTGAGTGTCCGGC (SEQ. ID. NO. 2); and said primer sequence is as follows: rs6311-F: AGAGAGAACATAAATAAGGCTAGAAAACAGTA (SEQ. ID. NO. 3) and rs6311-R: CACTGTTGGCTTTGGATGGA (SEQ. ID. NO. 4). The test kit is used to determine genotype of a depression patient, in order to treat the depression patient with a combination of serotonin reuptake inhibitors (SSRI) and low dose risperidone. The actual dose of risperidone and the ratio between SSRIs and risperidone is determined by the genotype of the depression patient. The present invention determines human drug metabolism rate through a single nucleotide polymorphism and provides a platform to adjust the patient's treatment.
    Type: Application
    Filed: November 27, 2013
    Publication date: June 12, 2014
    Inventors: Wen E., Qingmei Kong, Xiaojing Zhang, Hong Shao, Zhenguo Zhao, Shuping Liu, Maomao Li, Xinxia Tian
  • Publication number: 20130126802
    Abstract: The present invention advantageously provides a high-voltage lithium battery cathode material and its general formula for the composition of the high-voltage lithium battery cathode material presented in this invention: LiMn1.5Ni0.5-XMXO4 Of which: 0<X?0.2, M represents one or several elements comprised by copper, zinc, magnesium, aluminum, cadmium, zirconium, and titanium. The present invention relates to a high-voltage lithium battery cathode material, which utilizes the liquid-phase co-precipitation method to dope transition metal elements, so that all elements could be mixed at the atomic level and obtain a relatively uniform product, stabilizing the crystal structure, avoiding the capacity attenuation caused by structure collapse in the material cyclic process; in addition, this invention has also increased the conductivity, improved the capacity of 5 V platform, thereby avoiding the substantial damage to the battery system resulted from the decomposition of the electrolyte.
    Type: Application
    Filed: November 24, 2010
    Publication date: May 23, 2013
    Applicant: CITIC GUOAN MENGGULI POWER TECHNOLOGY CO., LTD.
    Inventors: Ningning Wu, Guopeng Teng, Wen E. Song, Yuan Chen, Yahe Wang, Huanzeng Ge